Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

InflaRx Announces GOHIBIC (Vilobelimab) Selected By BARDA For Phase 2 Study On Acute Respiratory Distress Syndrome; One Of Three Investigational Therapies Chosen By U.S. Department Of Health And Human Services

Author: Benzinga Newsdesk | June 24, 2024 08:04am

DSMB Recommends Continuation without Modification for Third Time
Safety Review Included 395 Patients
Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate
Low Event Rate Suggests Potential for Prolonged Survival
Rapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected

Posted In: IFRX